Metabolic adaptation
Both liraglutide (3 mg) and naltrexone/bupropion (32/360 mg) improved body weight and composition, carbohydrate and lipid metabolism, and liver fat and function.
Practitioners can consider both liraglutide and naltrexone/bupropion as effective options for improving metabolic health in patients with obesity.
Both medications improved body weight and composition, carbohydrate and lipid metabolism, and liver fat and function.
Why this rating
Based on the interventional study design with a defined treatment and assessment period.
Source
Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study
Konstantinos Stefanakis et al. · Diabetes Obesity and Metabolism · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →